Compare GECC & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GECC | LONA |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.6M | 81.5M |
| IPO Year | 2016 | 2020 |
| Metric | GECC | LONA |
|---|---|---|
| Price | $6.11 | $7.98 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $10.75 | $10.00 |
| AVG Volume (30 Days) | ★ 49.8K | 46.2K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | ★ 22.06% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.92 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.61 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.63 | $4.21 |
| 52 Week High | $11.45 | $14.21 |
| Indicator | GECC | LONA |
|---|---|---|
| Relative Strength Index (RSI) | 62.23 | 50.77 |
| Support Level | $5.38 | $6.86 |
| Resistance Level | $6.34 | $8.66 |
| Average True Range (ATR) | 0.18 | 0.55 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 80.56 | 35.63 |
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generates both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses. The Company operates as a single reportable segment with an investment objective to generate both current income and capital appreciation through debt and equity investments and manages the business on a consolidated basis.
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.